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xxx The field of genetic therapeutics, the focus of our new
journal, Genetic Vaccines and Therapy, is poised to enter a
potentially vast new arena of medical progress within this
decade. Worldwide interest exists among biopharmaceuti-
cal companies, governments, the military and medical
practitioners in the rapid development and deployment
of novel DNA-based agents. The possibilities are virtually
unlimited: new treatments for emerging and re-emerging
diseases; effective and specific immunization against the
viral scourges of HIV, smallpox and others; the genetic
correction of hereditary defects, such as cystic fibrosis;
more effective and specific antitumour therapies geneti-
cally tailored to the individual; and gene-specific preven-
tive measures for degenerative diseases such as
Alzheimer's, arthritis, and arteriosclerosis [1].
Much good and useful work has been done in the field of
genetic medicine, but much remains to be perfected.
Gene-based medicine has played a role and will continue
to be of critical importance in creating vaccines and anti-
viral therapies for HIV, hepatitis, herpes and other viruses,
in new strategies for the prevention and treatment of
emerging diseases, and for a secure and certain biodefense
plan against microbial attack. For example, cancer
patients may look forward to a swift and specific treat-
ment regimen based on detailed genetic analysis of their
tumour type and individual genetic makeup that can be
used to design DNA-based antitumour agents with mini-
mal side effects [2].
The burgeoning wealth of new information generated by
genome sequencing and gene chip analysis, combined
with the enhanced proteomics databases available today
opens up huge possibilities for designing new therapeutic
agents. The use of DNA to synthesize proteins with func-
tional or antagonistic properties is unlimited. DNA deliv-
ery methods that can potentially target DNA to a specific
type of cell or organ, or to a patient's specific tumour type,
are under intense investigation. Side effects arising from
system-wide application of a drug, as in chemotherapy
would be avoided by targeted DNA delivery. Maximum
efficacy will be obtained by getting the agent directly to
the area in need. The relatively long-lasting capacity of
DNAs to generate their products in situ alleviates the need
for continued dosing with potentially toxic and expensive
drugs.
As witnessed by the death of one gene therapy patient and
the development of leukemia in two others [3], the type
of delivery method and carrier for the DNA is of utmost
importance. While the research possibilities for designing
therapeutics are unlimited, they are only as good as the
safety and efficacy of the method of administration. We
must focus on the new information from genomics and
proteomics, but we cannot afford to overlook the need for
extremely rigorous research on gene delivery methods.
Research continues in designing viral vectors including
adenovirus, adeno-associated virus and lentivirus that are
devoid of adverse consequences [4]. In nonviral
approaches, nanoparticles of cationic lipids or other bio-
degradable polymers such as chitosan are also under
investigation [5,6].
The launch of our new open access online journal, Genetic
Vaccines and Therapy, will serve as a sounding board for
new research at the forefront of genetic engineering and
gene-delivery technology for the prevention and treat-
ment of disease. Open access means that all articles pub-
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lished in GVT will be freely available to all to read online
or download. The elimination of the hard-copy print for-
mat will decrease the cost of publication considerably,
and the absence of subscription fees will increase reader-
ship and dissemination of new research findings all over
the world. The democratization of science is finally
achievable through open access.
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